Target Information

Target General Infomation
Target ID
T37742
Former ID
TTDR00446
Target Name
Serum amyloid P-component
Gene Name
APCS
Synonyms
9.5S alpha-1-glycoprotein; SAP; APCS
Target Type
Clinical Trial
Disease Amyloidosis [ICD9: 277.3; ICD10: E85]
Parkinson's disease [ICD9: 332; ICD10: G20]
Function
Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin.
BioChemical Class
Pentraxin family
UniProt ID
P02743
Sequence
MNKPLLWISVLTSLLEAFAHTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYS
DLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESS
SGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWD
SVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV
Drugs and Mode of Action
Drug(s) CPHPC Drug Info Phase 1/2 Parkinson's disease [525166], [543014]
GSK-2315698 Drug Info Phase 1 Amyloidosis [524198]
GSK2398852 Drug Info Phase 1 Amyloidosis [524198], [543013]
Modulator CPHPC Drug Info
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
Reactome Amyloid formation
WikiPathways Human Complement System
Amyloids
References
Ref 524198ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
Ref 525166ClinicalTrials.gov (NCT02425241) Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination. U.S. National Institutes of Health.
Ref 543013(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8255).
Ref 543014(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8256).
Ref 524198ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
Ref 531012PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15.
Ref 544468Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.